The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
NCT ID: NCT02387359
Last Updated: 2019-06-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1054 participants
INTERVENTIONAL
2014-12-31
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
NCT01722318
Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
NCT02493452
Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT03596905
Long Term Safety Study of Plecanatide
NCT02706483
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT03573908
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Screening/Baseline: Patients will undergo an up to 28-day Screening/Baseline period to allow for any necessary diagnostic procedures, allow for required washout of medications and to determine study eligibility. If otherwise eligible based on screening criteria, patients will undergo a 2-week baseline assessment using an electronic diary where they will record daily assessments of bowel movements (BMs), stool consistency (Bristol Stool Form Scale-BSFS), abdominal pain and other IBS-related symptoms. Data from the two-week electronic diary assessment just prior to the randomization visit will be used to confirm IBS-C and study eligibility as well as define the patient's baseline from which change will be determined.
Treatment: Patients who meet all entry criteria will be randomized (1:1:1) to one of three blinded treatment groups on Day 1 of the Treatment period. Patients will take an oral dose of study drug OD for 12 weeks and continue the daily electronic diaries (BMs, rescue medication use, abdominal pain, and other symptoms). During treatment weeks 4, 8, and 12, patients will return to the clinic to undergo safety and efficacy assessments.
Post-Treatment: For 2 weeks after completing dosing, patients will continue to complete daily electronic diaries. Patients will then return to the clinical site for a final follow-up visit during Week 14 following randomization.
The planned duration of participation in this study will be at least 116 days from signing of informed consent through post-treatment or up to approximately 135 days with visit windows considered.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
3.0 mg plecanatide
Plecanatide 3.0 mg dosed daily for 12 weeks
Plecanatide
6.0 mg plecanatide
Plecanatide 6.0 mg dosed daily for 12 weeks
Plecanatide
Matching placebo
Placebo dosed daily for 12 weeks
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Plecanatide
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Refusal or inability to complete daily Episodic (real-time) BM / RM calls, End of Day daily Calls, and/or complete electronic questionnaires
* BMI \> 35 or \< 18
* Women of child bearing potential who refuse to use an acceptable method of birth control for the duration of the trial
* Women who are pregnant or lactating
* Diagnosis of IBS-D or IBS-M
* Organic or obstructive disease of the small or large intestine
* Use of laxatives other than the study-supplied rescue medication (Dulcolax®, bisacodyl)
* Use of a prohibited concomitant medication within the time frame prior to screening outlined in the study protocol for that medication
* Unstable medical illness
* Bilirubin \> 3X ULN in the absence of a conjugation defect
* Any laboratory value \> 3X ULN unless discussed and approved by the study Medical Monitor
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bausch Health Americas, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul F.C. Eng, PhD
Role: STUDY_DIRECTOR
Synergy Pharmaceuticals Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Synergy Research Site
Athens, Alabama, United States
Synergy Research Site
Birmingham, Alabama, United States
Synergy Research Site
Dothan, Alabama, United States
Synergy Research Site
Foley, Alabama, United States
Synergy Research Site
Huntsville, Alabama, United States
Synergy Research Site
Montgomery, Alabama, United States
Synergy Research Site
Chandler, Arizona, United States
Synergy Research Site
Glendale, Arizona, United States
Synergy Research Site
Phoenix, Arizona, United States
Synergy Research Site
Tucson, Arizona, United States
Synergy Research Site
Tucson, Arizona, United States
Synergy Research Site
Conway, Arkansas, United States
Synergy Research Site
Little Rock, Arkansas, United States
Synergy Research Site
Little Rock, Arkansas, United States
Synergy Research Site
Anaheim, California, United States
Synergy Research Site
Artesia, California, United States
Synergy Research Site
Chula Vista, California, United States
Synergy Research Site
Corona, California, United States
Synergy Research Site
Encino, California, United States
Synergy Research Site
Fountain Valley, California, United States
Synergy Research Site
Fresno, California, United States
Synergy Research Site
Garden Grove, California, United States
Synergy Research Site
La Mesa, California, United States
Synergy Research Site
La Mirada, California, United States
Synergy Research Site
Laguna Hills, California, United States
Synergy Research Site
Lancaster, California, United States
Synergy Research Site
North Hollywood, California, United States
Synergy Research Site
Sacramento, California, United States
Synergy Research Site
San Bernardino, California, United States
Synergy Research Site
San Diego, California, United States
Synergy Research Site
Thousand Oaks, California, United States
Synergy Research Site
Upland, California, United States
Synergy Research Site
Upland, California, United States
Synergy Research Site
Broomfield, Colorado, United States
Synergy Research Site.
Centennial, Colorado, United States
Synergy Research Site
Bristol, Connecticut, United States
Synergy Research Site
Hamden, Connecticut, United States
Synergy Research Site
Boynton Beach, Florida, United States
Synergy Research Site
Brandon, Florida, United States
Synergy Research Site
DeLand, Florida, United States
Synergy Research Site
Fort Lauderdale, Florida, United States
Synergy Research Site
Homestead, Florida, United States
Synergy Research Site
Inverness, Florida, United States
Synergy Research Site
Jacksonville, Florida, United States
Synergy Research Site
Miami, Florida, United States
Synergy Research Site
Miami Lakes, Florida, United States
Synergy Research Site
Miami Springs, Florida, United States
Synergy Research Site
Orlando, Florida, United States
Synergy Research Site
Ormond Beach, Florida, United States
Synergy Research Site
Oviedo, Florida, United States
Synergy Research Site
Port Orange, Florida, United States
Synergy Research Site
St. Petersburg, Florida, United States
Synergy Research Site
Tampa, Florida, United States
Synergy Research Site
Atlanta, Georgia, United States
Synergy Research Site
Marietta, Georgia, United States
Synergy Research Site
Norcross, Georgia, United States
Synergy Research Site
Norcross, Georgia, United States
Synergy Research Site
Stockbridge, Georgia, United States
Synergy Research Site
Idaho Falls, Idaho, United States
Synergy Research Site
Idaho Falls, Idaho, United States
Synergy Research Site
Chicago, Illinois, United States
Synergy Research Site
Evanston, Illinois, United States
Synergy Research Site
Evergreen Park, Illinois, United States
Synergy Research Site
Rockford, Illinois, United States
Synergy Research Site
Evansville, Indiana, United States
Synergy Research Site
Augusta, Kansas, United States
Synergy Research Site
Newton, Kansas, United States
Synergy Research Site
Topeka, Kansas, United States
Synergy Research Site
Wichita, Kansas, United States
Synergy Research Site
Wichita, Kansas, United States
Synergy Research Site
Baton Rouge, Louisiana, United States
Synergy Research Site
Crowley, Louisiana, United States
Synergy Research Site
Mandeville, Louisiana, United States
Synergy Research Site
Metairie, Louisiana, United States
Synergy Research Site
Monroe, Louisiana, United States
Synergy Research Site
New Orleans, Louisiana, United States
Synergy Research Site
Shreveport, Louisiana, United States
Synergy Research Site
Baltimore, Maryland, United States
Synergy Research Site
Hagerstown, Maryland, United States
Synergy Research Site
Boston, Massachusetts, United States
Synergy Research Site
Chesterfield, Michigan, United States
Synergy Research Site
Flint, Michigan, United States
Synergy Research Site
Rochester, Michigan, United States
Synergy Research Site
Wyoming, Michigan, United States
Synergy Research Site.
Jackson, Mississippi, United States
Synergy Research Site
Hazelwood, Missouri, United States
Synergy Research Site
Omaha, Nebraska, United States
Synergy Research Site
Las Vegas, Nevada, United States
Synergy Research Site
Marlton, New Jersey, United States
Synergy Research Site
Albuquerque, New Mexico, United States
Synergy Research Site
Brooklyn, New York, United States
Synergy Research Site
Great Neck, New York, United States
Synergy Research Site
New Windsor, New York, United States
Synergy Research Site
New York, New York, United States
Synergy Research Site
North Massapequa, New York, United States
Synergy Research Site
Asheboro, North Carolina, United States
Synergy Research Site
Cary, North Carolina, United States
Synergy Research Site
Charlotte, North Carolina, United States
Synergy Research Site
Charlotte, North Carolina, United States
Synergy Research Site
Concord, North Carolina, United States
Synergy Research Site
Davidson, North Carolina, United States
Synergy Research Site
Greensboro, North Carolina, United States
Synergy Research Site
Kinston, North Carolina, United States
Synergy Research Site
Lenoir, North Carolina, United States
Synergy Research Site
Raleigh, North Carolina, United States
Synergy Research Site
Wilmington, North Carolina, United States
Synergy Research Site
Winston-Salem, North Carolina, United States
Synergy Research Site
Fargo, North Dakota, United States
Synergy Research Site
Beavercreek, Ohio, United States
Synergy Research Site
Cincinnati, Ohio, United States
Synergy Research Site
Cleveland, Ohio, United States
Synergy Research Site
Cleveland, Ohio, United States
Synergy Research Site
Englewood, Ohio, United States
Synergy Research Site
Sylvania, Ohio, United States
Synergy Research Site
Oklahoma City, Oklahoma, United States
Synergy Research Site
Tulsa, Oklahoma, United States
Synergy Research Site
Portland, Oregon, United States
Synergy Research Site
Levittown, Pennsylvania, United States
Synergy Research Site
Philadelphia, Pennsylvania, United States
Synergy Research Site
Pittsburgh, Pennsylvania, United States
Synergy Research Site
Smithfield, Pennsylvania, United States
Synergy Research Site
Uniontown, Pennsylvania, United States
Synergy Research Site
Columbia, South Carolina, United States
Synergy Research Site
Gaffney, South Carolina, United States
Synergy Research Site.
Greer, South Carolina, United States
Synergy Research Site
North Charleston, South Carolina, United States
Synergy Research Site
Rapid City, South Dakota, United States
Synergy Research Site
Athens, Tennessee, United States
Synergy Research Site
Chattanooga, Tennessee, United States
Synergy Research Site
Memphis, Tennessee, United States
Synergy Research Site.
Nashville, Tennessee, United States
Synergy Research Site
Arlington, Texas, United States
Synergy Research Site
Austin, Texas, United States
Synergy Research Site
Austin, Texas, United States
Synergy Research Site
Carrollton, Texas, United States
Synergy Research Site
Dallas, Texas, United States
Synergy Research Site
Houston, Texas, United States
Synergy Research Site
Houston, Texas, United States
Synergy Research Site
Plano, Texas, United States
Synergy Research Site
San Antonio, Texas, United States
Synergy Research Site
Webster, Texas, United States
Synergy Research Site
Bountiful, Utah, United States
Synergy Research Site
Ogden, Utah, United States
Synergy Research Site
Sandy City, Utah, United States
Synergy Research Site
St. George, Utah, United States
Synergy Research Site
Alexandria, Virginia, United States
Synergy Research Site
Charlottesville, Virginia, United States
Synergy Research Site
Lynchburg, Virginia, United States
Synergy Research Site
Newport News, Virginia, United States
Synergy Research Site
Bellevue, Washington, United States
Synergy Research Site
Spokane, Washington, United States
Synergy Research Site
Charleston, West Virginia, United States
Synergy Research Site
Morgantown, West Virginia, United States
Synergy Research Site
Milwaukee, Wisconsin, United States
Synergy Research Site
Wauwatosa, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cash BD, Sharma A, Walker A, Laitman AP, Chang L. Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation. Neurogastroenterol Motil. 2023 Sep;35(9):e14632. doi: 10.1111/nmo.14632. Epub 2023 Jun 18.
Menees SB, Franklin H, Chey WD. Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older. Clin Ther. 2020 Jul;42(7):1406-1414.e4. doi: 10.1016/j.clinthera.2020.05.012. Epub 2020 Jul 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SP304203-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.